LUNG
VENTE TOTALE: 41 882 titres (~94 653,32 $ US)
- Insiders
- French Glendon E. III
- Total bought
- —
- Total sold
- $94,653
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-04
LUNG presents a deeply concerning financial profile with persistent negative operating margins, severe cash burn, and a broken business model that undermines any investment thesis.
The first sentence of the analysis written for LUNG on 2026-09-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.2% | 74.0% | 73.9% | 74.3% | 73.6% | |
| Ebit Margin | -55.5% | -62.5% | -83.1% | -107.2% | -98.1% | |
| Ebitda Margin | -54.3% | -60.6% | -80.2% | -104.3% | -96.3% | |
| Operating Profit Margin | -59.3% | -68.9% | -90.2% | -109.3% | -97.7% | |
| Pretax Profit Margin | -59.0% | -66.7% | -87.8% | -109.1% | -99.8% | |
| Continuous Operations Profit Margin | -59.7% | -67.3% | -88.6% | -109.8% | -100.5% | |
| Net Profit Margin | -59.7% | -67.3% | -88.6% | -109.8% | -100.5% | |
| Bottom Line Profit Margin | -59.7% | -67.3% | -88.6% | -109.8% | -100.5% | |
| Current Ratio | 5.069 | 5.575 | 6.496 | 9.137 | 11.852 | |
| Quick Ratio | 4.280 | 4.883 | 5.773 | 8.349 | 10.924 | |
| Solvency Ratio | -0.704 | -0.711 | -0.990 | -1.447 | -1.140 | |
| Cash Ratio | 3.490 | 2.902 | 3.608 | 5.502 | 8.460 | |
| Price To Earnings Ratio | -1.662 | -4.715 | -7.969 | -5.302 | -23.756 | |
| Price To Earnings Growth Ratio | 0.218 | 0.472 | -12.670 | -0.298 | -0.475 | |
| Forward Price To Earnings Growth Ratio | 0.218 | 0.472 | -12.670 | -0.298 | -0.475 | |
| Price To Earnings Diluted Ratio | -1.662 | -4.715 | -7.969 | -5.302 | -23.756 | |
| Price To Earnings Diluted Growth Ratio | 0.218 | 0.472 | -12.670 | -0.298 | -0.475 | |
| Price To Book Ratio | 1.662 | 3.095 | 4.092 | 2.031 | 5.996 | |
| Price To Sales Ratio | 0.994 | 3.169 | 7.050 | 5.828 | 23.932 | |
| Price To Free Cash Flow Ratio | -2.733 | -8.051 | -12.603 | -6.732 | -25.691 | |
| Price To Operating Cash Flow Ratio | -2.771 | -8.421 | -12.874 | -6.928 | -27.968 | |
| Debt To Assets Ratio | 0.436 | 0.347 | 0.233 | 0.126 | 0.113 | |
| Debt To Equity Ratio | 1.042 | 0.658 | 0.350 | 0.158 | 0.137 | |
| Debt To Capital Ratio | 0.510 | 0.397 | 0.259 | 0.137 | 0.120 | |
| Long Term Debt To Capital Ratio | 0.406 | 0.284 | 0.229 | 0.101 | 0.082 | |
| Financial Leverage Ratio | 2.389 | 1.898 | 1.503 | 1.258 | 1.217 | |
| Working Capital Turnover Ratio | 0.936 | 0.701 | 0.495 | 0.315 | 0.226 | |
| Operating Cash Flow Ratio | -1.618 | -1.291 | -1.624 | -2.441 | -2.361 | |
| Operating Cash Flow Sales Ratio | -0.359 | -0.376 | -0.548 | -0.841 | -0.856 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | 1.046 | 1.021 | 1.029 | 1.089 | |
| Debt Service Coverage Ratio | -11.137 | -7.675 | -10.333 | -48.740 | -51.049 | |
| Interest Coverage Ratio | -17.009 | -16.454 | -19.163 | -55.007 | -57.062 | |
| Short Term Operating Cash Flow Coverage Ratio | -24.655 | -9.930 | -17.452 | -501.511 | -455.264 | |
| Operating Cash Flow Coverage Ratio | -0.576 | -0.558 | -0.908 | -1.850 | -1.566 | |
| Capital Expenditure Coverage Ratio | -71.783 | -21.795 | -46.605 | -34.246 | -11.285 | |
| Dividend Paid And Capex Coverage Ratio | -71.783 | -21.795 | -46.605 | -34.246 | -11.285 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.551 | -4.944 | -8.024 | -4.204 | -22.235 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.2% | ▲0.2% | ▲0.2% |
| Ebit Margin | -55.5% | ▲7.0% | ▲25.8% |
| Ebitda Margin | -54.3% | ▲6.3% | ▲24.8% |
| Operating Profit Margin | -59.3% | ▲9.6% | ▲25.8% |
| Pretax Profit Margin | -59.0% | ▲7.7% | ▲25.5% |
| Continuous Operations Profit Margin | -59.7% | ▲7.6% | ▲25.5% |
| Net Profit Margin | -59.7% | ▲7.6% | ▲25.5% |
| Bottom Line Profit Margin | -59.7% | ▲7.6% | ▲25.5% |
| Current Ratio | 5.069 | ▼-0.506 | ▼-2.556 |
| Quick Ratio | 4.279 | ▼-0.604 | ▼-2.562 |
| Solvency Ratio | -0.704 | ▲0.007 | ▲0.294 |
| Cash Ratio | 3.490 | ▲0.589 | ▼-1.302 |
| Price To Earnings Ratio | -1.662 | ▲3.054 | ▲7.019 |
| Price To Earnings Growth Ratio | 0.217 | ▼-0.254 | ▲2.768 |
| Forward Price To Earnings Growth Ratio | 0.217 | ▼-0.254 | ▲2.768 |
| Price To Earnings Diluted Ratio | -1.662 | ▲3.054 | ▲7.019 |
| Price To Earnings Diluted Growth Ratio | 0.217 | ▼-0.254 | ▲2.768 |
| Price To Book Ratio | 1.661 | ▼-1.433 | ▼-1.714 |
| Price To Sales Ratio | 0.994 | ▼-2.176 | ▼-7.201 |
| Price To Free Cash Flow Ratio | -2.733 | ▲5.318 | ▲8.429 |
| Price To Operating Cash Flow Ratio | -2.771 | ▲5.649 | ▲9.021 |
| Debt To Assets Ratio | 0.436 | ▲0.089 | ▲0.185 |
| Debt To Equity Ratio | 1.042 | ▲0.383 | ▲0.573 |
| Debt To Capital Ratio | 0.510 | ▲0.113 | ▲0.226 |
| Long Term Debt To Capital Ratio | 0.406 | ▲0.122 | ▲0.186 |
| Financial Leverage Ratio | 2.389 | ▲0.491 | ▲0.736 |
| Working Capital Turnover Ratio | 0.936 | ▲0.235 | ▲0.401 |
| Operating Cash Flow Ratio | -1.618 | ▼-0.327 | ▲0.249 |
| Operating Cash Flow Sales Ratio | -0.358 | ▲0.018 | ▲0.237 |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | ▼-0.032 | ▼-0.026 |
| Debt Service Coverage Ratio | -11.137 | ▼-3.462 | ▲14.650 |
| Interest Coverage Ratio | -17.009 | ▼-0.555 | ▲15.930 |
| Short Term Operating Cash Flow Coverage Ratio | -24.655 | ▼-14.725 | ▲177.107 |
| Operating Cash Flow Coverage Ratio | -0.576 | ▼-0.017 | ▲0.516 |
| Capital Expenditure Coverage Ratio | -71.783 | ▼-49.988 | ▼-34.640 |
| Dividend Paid And Capex Coverage Ratio | -71.783 | ▼-49.988 | ▼-34.640 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.551 | ▲3.393 | ▲6.641 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $89.9M | $265.6M | $484.2M | $312.7M | $1.16B | |
| Enterprise value | $76.3M | $251.1M | $442.1M | $235.4M | $1.04B | |
| EV / Sales | 0.84x | 3.00x | 6.44x | 4.39x | 21.41x | |
| EV / Op. cash flow | -2.35x | -7.96x | -11.75x | -5.21x | -25.02x | |
| EV / Free cash flow | -2.32x | -7.61x | -11.51x | -5.07x | -22.99x | |
| EV / EBITDA | -1.55x | -4.94x | -8.02x | -4.20x | -22.23x | |
| Net debt / EBITDA | 0.28x | 0.28x | 0.77x | 1.38x | 2.62x | |
| Current ratio | 5.07x | 5.58x | 6.50x | 9.14x | 11.85x | |
| Income quality | 0.60x | 0.56x | 0.62x | 0.77x | 0.85x | |
| Graham net-net | $0 | $1 | $2 | $3 | $4 | |
| Tax burden | 101.2% | 100.9% | 100.9% | 100.6% | 100.7% | |
| Interest burden | 106.3% | 106.7% | 105.7% | 101.9% | 101.7% | |
| Working capital | $81.6M | $111.8M | $127.3M | $150.5M | $190.5M | |
| Invested capital | $104.9M | $135.6M | $137.1M | $163.4M | $206.0M | |
| Return on assets | -41.8% | -34.6% | -34.2% | -30.4% | -20.7% | |
| Operating ROA | -36.7% | -33.9% | -33.3% | -27.3% | -19.0% | |
| Return on tangible assets | -42.8% | -35.1% | -34.7% | -30.8% | -20.9% | |
| Return on equity | -99.8% | -65.7% | -51.4% | -38.3% | -25.2% | |
| Return on invested capital | -48.5% | -40.5% | -38.7% | -32.8% | -21.5% | |
| Return on capital employed | -49.1% | -41.7% | -40.1% | -33.5% | -21.7% | |
| Earnings yield | -60.1% | -21.2% | -12.6% | -18.8% | -4.2% | |
| Free cash flow yield | -36.6% | -12.4% | -7.9% | -14.9% | -3.9% | |
| Capex / Op. cash flow | -1.4% | -4.6% | -2.1% | -2.9% | -8.9% | |
| Capex / Depreciation | 39.2% | 96.9% | 52.1% | 33.0% | 116.2% | |
| Capex / Sales | 0.5% | 1.7% | 1.2% | 2.5% | 7.6% | |
| SG&A / Sales | 111.9% | 121.9% | 137.8% | 154.9% | 144.3% | |
| R&D / Sales | 21.5% | 21.0% | 26.3% | 28.7% | 27.0% | |
| Stock comp / Sales | 0.0% | 27.4% | 32.2% | 0.0% | 0.0% | |
| Intangibles / Total assets | 2.3% | 1.4% | 1.3% | 1.3% | 1.1% | |
| Days sales outstanding | 49d | 60d | 69d | 63d | 52d | |
| Days payables outstanding | 61d | 64d | 30d | 47d | 45d | |
| Operating cycle | 296d | 343d | 410d | 448d | 517d | |
| Cash conversion cycle | 235d | 279d | 380d | 402d | 472d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-66.1%EV / Sales ▼-71.9%EV / EBITDA ▲+68.6%EV / Op. cash flow ▲+5.612Earnings yield ▼-0.388
Profitability
Return on equity ▼-0.341Return on assets ▼-0.071Return on invested capital ▼-0.080Return on capital employed ▼-0.074Operating ROA ▼-0.029Income quality ▲+0.042Tax burden ▲+0.003
Efficiency
Days sales outstanding ▼-11.386Days payables outstanding ▼-3.090Operating cycle ▼-47.153Cash conversion cycle ▼-44.062Capex / Sales ▼-0.012R&D / Sales ▲+0.006
Balance-sheet strength
Current ratio ▼-0.506Net debt / EBITDA ▼-0.007Working capital ▼-30185000.000Invested capital ▼-30689000.000Intangibles / Total assets ▲+0.009
Change over 5 years
Valuation
Market cap ▼-92.2%EV / Sales ▼-96.1%EV / EBITDA ▲+93.0%EV / Op. cash flow ▲+22.672Earnings yield ▼-0.559
Profitability
Return on equity ▼-0.746Return on assets ▼-0.211Return on invested capital ▼-0.270Return on capital employed ▼-0.274Operating ROA ▼-0.178Income quality ▼-0.251Tax burden ▲+0.005
Efficiency
Days sales outstanding ▼-3.509Days payables outstanding ▲+15.860Operating cycle ▼-220.795Cash conversion cycle ▼-236.655Capex / Sales ▼-0.071R&D / Sales ▼-0.054
Balance-sheet strength
Current ratio ▼-6.782Net debt / EBITDA ▼-2.340Working capital ▼-108826000.000Invested capital ▼-101044000.000Intangibles / Total assets ▲+0.012
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-02 Deutsche Bank AG Takes Position in Pulmonx Corporation $LUNG Deutsche Bank AG purchased a new stake in Pulmonx Corporation (NASDAQ: LUNG) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 402,316 shares of the company''s stock, valued at approximately $523,000. Deutsche Bank AG owned approximately 0.94% of
- 2026-09-01 Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company''s Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
- 2026-08-27 Pulmonx to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
- 2026-08-26 Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy? After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
- 2026-08-15 Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
- 2026-08-14 What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-03 Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock? Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-07-30 Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript
- 2026-07-29 Pulmonx Q2 Earnings Call Highlights Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China.
- 2026-07-29 Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.38 per share a year ago.